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Ipratropium, a short-acting anticholinergic bronchodila-
tor, is frequently prescribed for the maintenance treat-
ment of COPD. Tiotropium is a new, once-daily bron-
chodilator.
OBJECTIVE: To compare the costs and consequences of
tiotropium versus ipratropium in COPD patients with a
FEV 1 65% of predicted normal.
METHODS: The cost-consequence analysis was part of a
one-year, randomized, controlled, double-blind clinical
trial in the Netherlands and Belgium. Consequences were
expressed as the number of COPD exacerbations, the
number of patients with a minimal clinically relevant im-
provement in the St. George’s Respiratory Questionnaire
(SGRQ), and the number of effectively treated patients.
A societal perspective was adopted when calculating
COPD-related direct health-care costs. Multiple imputa-
tion (SOLAS) was used to impute all missing data.
RESULTS: Tiotropium was associated with a 27% re-
duction in exacerbations (p  0.03). The number of pa-
tients with a clinically relevant improvement in SGRQ af-
ter one year of treatment was 16% higher in tiotropium
(p  .001). The proportion of effectively treated patients
was 21% higher (p  .001). Across all categories, health-
care resource use was consistently lower for tiotropium
than for ipratropium. There was a 47% reduction (p 
0.07) in the number of hospital admissions and a 36%
reduction (p  0.03) in the number of unscheduled visits
to physicians and other caregivers. The use of concomi-
tant medication was comparable in both groups. COPD-
related health-care costs were estimated to be Euro 1310
in ipratropium and Euro 1065 in tiotropium. Hence, an-
nual savings were estimated to be Euro 245 with a 95%
CI ranging from 656 to 167. This estimate excludes
the costs of the study medications, since the price of
tiotropium still has to be set.
CONCLUSION: This cost-consequence analysis favors
the new once daily bronchodilator tiotropium over iprat-
ropium on all relevant outcome measures.
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OBJECTIVE: To determine if lost productive work time
differed between individuals with and without AR symp-
toms and by severity of AR symptoms. Work loss was
evaluated as: a) missed workdays; b) missed hours, and c)
reduced productivity on days at work while not feeling
well.
METHODS: Three different phone interviews were de-
veloped to quantify illness-related work loss. Version 1
(V1) included a lengthy direct assessment of work loss.
Version 2 (V2) was an abridged version of V1. Version 3
(V3) included a brief indirect assessment of work loss.
Two different recall periods, at one week and at four
weeks, were used for each version of the interview. A
convenience sample (n  20,088) of adult residents from
the Baltimore, MD and Chicago, IL areas was contacted
by phone, of whom 7,691 met occupation eligibility cri-
teria. The interview included health questions to screen
for AR symptoms and to determine AR severity.
RESULTS: The dominant source of health-related work
loss among all respondents was in total hours of reduced
productive work time on days at work when not feeling
well, rather than missed full days of work. We compared
individuals with AR symptoms (n  1,596) to controls
without AR symptoms on the basis of estimates of total
hours of lost productive work time per week by interview
version. AR cases reported significantly more lost pro-
ductive work hours per week than controls. The observed
differences between cases and controls per week were 1.8
hours (V1), 2.1 hours (V2), and 3.1 hours (V3) (p  .05).
Among moderate-to-severe AR cases, the observed differ-
ences per week increased to 4.4 hours (V1), 5.7 hours
(V2), and 6.5 hours (V3).
CONCLUSION: Individuals with AR symptoms re-
ported significantly more lost productive time at work on
days at work when not feeling well than controls. Hours
of lost productive work time per week increased with in-
creased severity of AR symptoms.
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OBJECTIVES: To assess the impact of an intervention
helping physicians in the management of asthma patients
(APs).
METHODS: A program was designed to help physicians
in the management of APs that includes an education
program (EP) and a computer application (CA) advising
on therapeutic decisions. The EP was devoted to teach
patients to distinguish worsening symptoms requiring a
hospital emergency visit from those that could be self-
managed, and to ensure correct self-administration/self-
control of therapy. The CA implements the Spanish rec-
ommendations for the management of APs that physi-
cians may follow at their discretion. A naturalistic, con-
trolled, cluster-randomized study was designed to assess
the long-term (one-year) impact of the intervention on
health-related quality of life as measured by the St.
George’s Respiratory Questionnaire (SGRQ), on direct
and indirect costs, and on satisfaction and clinical out-
comes. We also assessed physicians’ adherence to the rec-
ommendations. Twenty-two physicians (11 GPs, 11 pneu-
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mologists) were randomly assigned to either intervention
(I) or control (C  standard practice) groups, and were
expected to enroll 10 adult patients with persistent
asthma (ATS criteria).
RESULTS: Two physicians withdrew after randomiza-
tion (I:1, C:1) but before starting recruitment. A total of
200 patients ( I:100, C:100) were recruited and 173 com-
pleted the study (C:86, I:87). The ITT analysis showed a
greater reduction of SGRQ values in group I that was sig-
nificant at the 5% level or marginally non-significant (p 
0.06) depending on the method of analysis, but always
clinically significant. Resource consumption and some
clinical variables (such as the number of symptom-free
days and nights) favored group I (p  0.05). The recom-
mendations were adopted in about 63% of the cases but
this seemed to depend on disease severity.
CONCLUSIONS: The intervention improved QoL, clini-
cal outcomes and resource consumption. The Spanish
recommendations for the management of APs should be
revised for severe cases.
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OBJECTIVE: The aim of the study was to assess the cost-
effectiveness of almitrine in the treatment of severe,
chronic obstructive pulmonary disease.
METHODS: A retrospective approach was applied. Both
costs and consequences of the therapy in two groups of
patients, almitrine group and placebo group, were as-
sessed. The pharmacoeconomic analysis was based on the
results of a clinical trial entitled “Effects of sequential ad-
ministration of almitrine bismesylate (100mg per day per
os) in 120 patients with chronic obstructive pulmonary
disease. One year, double blind study versus placebo”.
The effectiveness of the therapies was exemplified by sig-
nificant changes in arterial oxygen partial pressure (D
PaO2). The differences on Visual Analogue Scale for dys-
pnoea were also measured. Results of the trial demon-
strated significant improvement in PaO2 during 12-
months of treatment with almitrine compared to placebo.
Direct medical costs of pharmacological treatment, hos-
pitalizations, additional examinations and oxygen ther-
apy were identified and calculated. The societal and
third-party-payer perspectives were applied.
RESULTS: The total cost per patient per year in the alm-
itrine group amounted to 2 656 PLN and was 27 PLN
lower than for the placebo group. The most important
difference in cost components concerned costs of hospi-
talizations and oxygen therapy, which were 47.4% and
34.5% lower in almitrine group (calculations made from
societal perspective). Results of simulation assuming pos-
sibility of partial, subtotal or total reimbursement deter-
mined that savings due to this procedure might vary from
93 PLN per patient per year in the case of total reim-
bursement to 531 PLN per patient per year in the case of
50% reimbursement.
CONCLUSION: Cost calculations together with clinical
results determined that treatment with almitrine is a cost-
effective alternative, which leads to clinical improvement
and constitutes effective use of resources both from the
broad societal perspective and also from the third-party-
payer perspective.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease
(COPD) causes great disability, primarily among the el-
derly. A Dutch cost-of-illness study estimated the yearly
cost of care for an average patient to be Fl 1800 in 1993.
The purpose of this paper is to compute the lifetime cost
of COPD and to evaluate the contribution of medication,
hospital, and other types of care to this cost.
METHODS: The average life expectancy of a new COPD
patient was computed with a dynamic lifetable model for
the Netherlands. The model accounts for competing
death risks from other smoking-related diseases. Re-
source use and costs for three age groups and nine types
of care came from large representative registries. Sensitiv-
ity analyses were performed a/o., for the cost of a day in
hospital and for medication costs.
RESULTS: Male COPD patients diagnosed at age 45 and
65 have a life expectancy that is almost six and more
than two years less than the average life expectancy at
these ages. Expected lifetime costs for COPD are between
DFL 460 000 and 570 000 for men and women diag-
nosed at age 45. New patients at age 65 have lower costs:
between DFL 81 000 and 110 000 for men and DFL 102
000 and 152 000 for women. A large decrease in life ex-
pectancy that differs for men and women explains the re-
duction. Lower boundaries use minimum estimates for
the price of a hospital day and upper boundaries use high
estimates. Hospital and medication costs together con-
tribute to more than 80% of total lifetime cost. The con-
tribution of medication costs to the expected lifetime cost
decreases with age at diagnosis from 45% to 30%.
CONCLUSION: The lifetime cost reflects the importance
of hospital costs and medication costs to the total cost of
COPD. It is known that the number of COPD patients
will increase in the near future. The results of this work
may help understand the increasing health-care needs of
these patients.
